Collegium Pharmaceutical
COLL
72 hedge funds and large institutions have $307M invested in Collegium Pharmaceutical in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 38 increasing their positions, 16 reducing their positions, and 16 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 16
31% more capital invested
Capital invested by funds: $235M → $307M (+$72.2M)
4.03% more ownership
Funds ownership: 79.3% → 83.33% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 83 → 72 (-11)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
72% less call options, than puts
Call options by funds: $149K | Put options by funds: $529K
Top Buyers
| 1 |
CCM
Cadian Capital Management
New York
|
+$8.9M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$5.23M |
| 3 |
BlackRock
New York
|
+$3.66M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$2.99M |
| 5 |
Millennium Management
New York
|
+$2.6M |
Top Sellers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.99M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$3.77M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$2.01M |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.69M |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$1.09M |
COLL Hedge Fund Activity: Q2 2017 in Review
72 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2017, worth a combined $307M — up 31% from $235M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of COLL and 7 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 38 added.
The largest buyer was Cadian Capital Management, adding an estimated $8.9M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $7.99M sold.
- 72 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2017, down from 83 in Q1 2017.
- Funds reported $307M of Collegium Pharmaceutical stock for Q2 2017, up 31% quarter-over-quarter.
- 7 funds opened new Collegium Pharmaceutical positions in Q2 2017 and 16 closed out, a net change of -9 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2017 was Cadian Capital Management, an estimated $8.9M added.
- The largest Collegium Pharmaceutical seller in Q2 2017 was PFM Health Sciences, an estimated $7.99M sold.
Based on aggregated 13F filings for Q2 2017.